GlassScriptPhysician profile
Caleb M Rowe
NPI 1538531868
$9,378.44
in general payments reported to CMS, 2019-2025
28 companies · $2,882 in 2025
The $2,882 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $587 · 2022: $2,570 · 2023: $1,207 · 2024: $2,133 · 2025: $2,882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,852 · Education: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,851.82 |
| Education | $369.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,995.84 | 2021-2025 | |
| Janssen Biotech, INC. | $1,501.46 | 2022-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $1,042.54 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $681.73 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $489.21 | 2022-2025 | Odomzo, Blu-U |
| Galderma Laboratories, L.P. | $488.53 | 2021-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $433.47 | 2021-2025 | |
| Leo Pharma INC. | $315.85 | 2022-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $267.29 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $263.29 | 2022-2024 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.79 | 2022-2025 | Spevigo |
| Ucb, INC. | $221.01 | 2021-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $215.36 | 2023-2025 | Zoryve |
| Pfizer INC. | $206.74 | 2021-2024 | |
| Amgen INC. | $204.13 | 2022-2025 | Otezla, Otezla |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $178.63 | 2021-2025 | Opzelura |
| Almirall LLC | $110.09 | 2022-2025 | Klisyri, Seysara |
| Biofrontera INC. | $105.95 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $89.53 | 2022-2025 | Cabtreo |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Dermavant Sciences, INC. | $43.28 | 2023-2024 | Vtama |
| Journey Medical Corporation | $40.75 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $38.25 | 2025 | Acthar |
| Fresenius Kabi USA, LLC | $30.61 | 2023 | Idacio |
| Botanix Sb INC | $28.74 | 2025 | Sofdra |
| Convatec INC. | $20.42 | 2024 | |
| Lnhc, INC | $17.27 | 2025 | Zelsuvmi |
| Verrica Pharmaceuticals INC. | $13.69 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Rowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.